Fears are mounting about job losses, not having enough money to pay the bills, and those dwindling retirement funds.
All that worry can add up to a lot of stress. Research shows that a little stress is good, but too much anxiety can cause health problems.
Here are a few tips to unwind:
Limit information overload. Take regular breaks from your cell phone and email. Also, read a uplifting book instead of the newspaper or business magazine.
Exercise to music. The combination seems to change brain waves to a relaxation mode.
Take in a movie. Either at home or in the theater, the benefit is a several hour period where you literally escape from the world and it's problems.
Activate your brain's pleasure center. One of the best ways to do that is eating a piece of dark chocolate. That's right ladies, enjoy!
Taken as a pill once a day, it could make treatment for millions easier, more effective
Small, early study used electrical nerve stimulation and tone therapy for hard-to-treat tinnitus
Following a healthy diet runs about $1.50 more a day than junk food, study finds
'Insulin sensitizers' tied to lower odds of developing cancer when compared to other type of medication
What Happens If My Income Changes After I Receive An Insurance Subsidy?
In one of the biggest advances against leukemia and other blood cancers in many years, doctors are reporting unprecedented success by using gene therapy to transform patients' blood cells into soldiers that seek and destroy cancer.
By Tova Cohen TEL AVIV (Reuters) - Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, estimates its pipeline of so-called new therapeutic entities (NTEs) could generate revenue of $1 billion to $1.5 billion by 2018. This figure could jump to $3 billion in 2020, Elisabeth Kogan, Teva's senior vice president of generic research and development, told reporters on Sunday. The NTE program, launched a year ago, is a major element in Teva's strategy for growth and the company has 15 such products in its pipeline. One such product, called Adasuve, which it licensed from Alexza Pharmaceuticals, has been approved and is expected to be launched in the United States in about a month, Teva officials said.